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  Male rats， weighing 300 to 350 gra皿s， were nephrectolnized bilaterally and their penis was ligated．
The bladder was instilled with O。7 ml of normal saline． This was designated as the intravesica田uid．
  Antibacterial agents such as kanamycin， DKB， gentamicin， cefamezin， rifampicin and nalidixic
acid were administered to these rats 100 mg per 1 kg body wei，ght． Forty－eight hours later， ＄erum
and intravesical fluid were submitted for thin－layer chromatographic bioautography． This procedure
was made also at 24 hours after administration in the nalidix acid group．
  No active metabolite was detected in kana．mycin， gentamicin， cefamezin and ri’fampicin． ln
DKB， serum sample occasionally showed the small inhibitory zone of a different Rf value from the
eriginal DKB， but an exact proof of being an active metabolite could not be obtained． ln nalidixic
acid， 24 hours sarnples， both serum and intravesical fluid， showed nalidixic acid as welr as hydroxy－
nalidixic ac量d． In 48 hours samples， both serum and the intravesica田uid， nalidixic acid could not





























 Kanamycin sulfate（KM：力価700 mcg／mg，明治
製菓株式会社）






 Nalidixic acid（NA：力価1，000 mcg／mg，第一製
薬株式会社）
 Rifampicin（RFP：力価1 ，OOO mcgfmg，第一製薬
株式会社）
A－3．検定菌株および使用培地




ム10g，寒天（栄研）10g，蒸溜水1，eOO ml， pH 7．2
 RFPの検出にはBacillus subtilis ATGC 6633を検
定菌とし，培地として普通寒天培地（栄研pH 7．0）
を使用した。















 Eastman chromogram shcct No，6061を使用した．







KM， DKIB， GMはO．1Mのリン酸緩衝液（pH 7．8）
で溶解し，KM  DKBは100 mg／kg of body weight
を，GMは40 mg／kg of body weightを， CEZは
0．15Mリン酸緩衝液（pH 7．0）で溶解したのち100
mgfkg of body weightを大腿筋肉内に投与した．
 NAは生理的食：塩水に0．1 N NaOHを加えた溶液
で溶解し，きらに0．1NHCIでpH 7・8に調整した
のち1 OO mg／kg of body weightを投与した．
 RFPはO．5％carboxymethylcerlose－Na水溶液に
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 Standard Serum The satine
Fig． 2． A bieautogram of DKB．
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48 hrs ofter 100mg／kg imi ini・
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Fig． 4． A bioautogram of CEZ．
Standard Serum The ＄ollne
Fig． 6． A bioautogram of NA．
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